Form 8-K - Current report:
SEC Accession No. 0001193125-25-016268
Filing Date
2025-01-30
Accepted
2025-01-30 07:52:31
Documents
17
Period of Report
2025-01-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d861286d8k.htm   iXBRL 8-K 38649
2 EX-1.1 d861286dex11.htm EX-1.1 236387
3 EX-4.1 d861286dex41.htm EX-4.1 85888
4 EX-5.1 d861286dex51.htm EX-5.1 11673
8 GRAPHIC g861286g0130043551457.jpg GRAPHIC 2732
  Complete submission text file 0001193125-25-016268.txt   594080

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA akro-20250128.xsd EX-101.SCH 2850
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE akro-20250128_lab.xml EX-101.LAB 17994
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akro-20250128_pre.xml EX-101.PRE 11261
19 EXTRACTED XBRL INSTANCE DOCUMENT d861286d8k_htm.xml XML 3653
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38944 | Film No.: 25571198
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)